ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tegafur

Also written as “S-1”, “S-1/Cisplatin” and “S-1, Irinotecan, Bevacizumab”.

Its studies are mostly in Stomach Neoplasms · Pancreatic Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Renal Insufficiency, led by 4 companies.

Drug pageTegafur: every studyAll 189 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 30, 200525 company-led studies, 1 open or runningNext primary completion: Jun 30, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsukaits history only190 open or runningphase 3since Jun 30, 2005Jun 30, 2005none ahead
TTY Biopharmits history only40 open or runningphase 2since Mar 26, 2015Jun 4, 2013none ahead
Innovent Biologics11 open or runningphase 2since Mar 16, 2026Mar 16, 2026Jun 30, 2030phase 2 · NCT07483567
Sanofiits history only10 open or runningphase 3since Jan 16, 2008Jan 16, 2008none ahead

Also a collaborator on its studies: Quintiles, United BioSource and Daiichi Sankyo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Innovent Biologics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2026First study: phase 2 study in CLDN18.2 PositiveFirst studyNCT07483567 · 90 planned · China

Ahead

  1. Jun 30, 2030Primary completion: phase 2 study in CLDN18.2 PositiveNCT07483567

TargetBeta

TYMS →read by rule
“RNA inhibitor; Thymidylate synthase inhibitor”ChEMBL 37, by rule

Other programs on TYMS

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
CapecitabineruleHoffmann-La Rochephase 4129
FluorouracilruleSanofiphase 482

Studies

The one study Innovent Biologics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07483567CLDN18.2 Positive · China2RecruitingJun 30, 203090

How it is read

Names in the registry

  • “S-1”, 8 entries
  • “S-1/Cisplatin”, 3 entries
  • “S-1, Irinotecan, Bevacizumab”, 2 entries
  • “IBI343,sintilimab,oxaliplatin,S-1”, 1 entry
  • “S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.